A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

NCT05194072 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

250

Enrollment

INDUSTRY

Sponsor class

Stopped The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns

Conditions

Ovarian Neoplasms
Peritoneal Neoplasms
Fallopian Tube Neoplasms
Triple Negative Breast Neoplasms
HER2 Negative Breast Neoplasms
Hormone Receptor Positive Breast Neoplasms
Endometrial Neoplasms
Carcinoma, Non-Small-Cell Lung
Cholangiocarcinoma
Gallbladder Carcinoma
Adenoid Cystic Carcinoma

Interventions

DRUG: Felmetatug Vedotin
DRUG: Pembrolizumab

Sponsor

Seagen, a wholly owned subsidiary of Pfizer